Related Experiment Videos
The anti-mycoplasmal activity of aminosidine
Abstract:
Some in vivo experiments of therapeutic activity in severe experimental infection (intracranial) in the mouse due to different strains of Mycoplasma proved the high efficacy of the antibiotic aminosidine when administered subcutaneously at the dose of 30 mg/kg and have also demonstrated that oral treatment is moderately effective against Mycoplasma hominis 2. Sensitivity test carried out in vitro on the same Mycoplasma strains confirmed the bactericidal activity of aminosidine. These experiments have therefore shown that the therapeutic spectrum of aminosidine, which includes Gram-positive, Gram-negative, acid-fast bacteria and some protozoa, may be enlarged to include the genus Mycoplasma. For this reason the antibiotic can find a useful application in the treatment of primary atypical neumonia. In addition, from a clinical research point of view, aminosidine may constitute a promising tool for the treatment of different illnesses in which Mycoplasma have been described as important co-factors of pathogenicity in man.
Insights
Aminosidine demonstrates high efficacy against Mycoplasma infections in mice, both subcutaneously and orally. This antibiotic
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Mycoplasma infections pose significant challenges in both veterinary and human medicine.
- Aminosidine is an established antibiotic with a known spectrum of activity against various bacterial and protozoal pathogens.
Purpose of the Study:
- To evaluate the efficacy of aminosidine against different strains of Mycoplasma.
- To determine the in vitro and in vivo activity of aminosidine against Mycoplasma species.
Main Methods:
- In vivo experiments were conducted using a mouse model with severe intracranial Mycoplasma infections.
- Subcutaneous and oral administration routes were tested at a dose of 30 mg/kg.
- In vitro sensitivity tests were performed on isolated Mycoplasma strains.
Main Results:
- Subcutaneous aminosidine (30 mg/kg) showed high therapeutic efficacy against experimental Mycoplasma infections in mice.
- Oral aminosidine demonstrated moderate effectiveness against Mycoplasma hominis.
- In vitro tests confirmed the bactericidal activity of aminosidine against Mycoplasma.
Conclusions:
- Aminosidine's therapeutic spectrum can be expanded to include Mycoplasma species.
- Aminosidine shows promise for treating primary atypical pneumonia and other Mycoplasma-related human illnesses.
- The antibiotic represents a valuable therapeutic option for infections where Mycoplasma acts as a co-pathogen.